AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
36Kr's 15min chart shows bullish signs with KDJ Golden Cross and Marubozu.
ByAinvest
Wednesday, Oct 8, 2025 11:04 am ET2min read
As per 36Kr's 15-minute chart, a bullish indicator has been triggered, namely the KDJ Golden Cross, coupled with a Bullish Marubozu at 10/08/2025 11:00. This suggests that the momentum of the stock price is shifting towards the upside, potentially leading to further increases. The control of the market is now in the hands of buyers, and it is likely that bullish momentum will continue.
Amgen Inc. (AMGN) has shown a significant shift in its stock price momentum, according to the latest technical analysis. As per 36Kr's 15-minute chart, a bullish indicator has been triggered, namely the KDJ Golden Cross, coupled with a Bullish Marubozu at 10/08/2025 11:00. This suggests that the momentum of the stock price is shifting towards the upside, potentially leading to further increases. The control of the market is now in the hands of buyers, and it is likely that bullish momentum will continue [1].Institutional investors have also shown increased confidence in Amgen. Dohj LLC, for instance, increased its stake in Amgen by 60% during the 2nd quarter, bringing its total holdings to 5,963 shares valued at approximately $1.66 million [1]. This is part of a broader trend where a significant number of institutional investors have enhanced their positions in Amgen, with notable increases including CBIZ Investment Advisory Services LLC raising its stake by 1,214.3% and Nova Wealth Management Inc. by 12,200% in the past quarter [1].
Additionally, insiders have also placed their bets on Amgen. SVP Nancy A. Grygiel sold 1,267 shares of the company's stock in a transaction that occurred on Wednesday, August 20th, but the sale represented a 14.95% decrease in their ownership of the stock [1]. Despite this, the senior vice president still owns 7,209 shares of the company's stock, valued at $2,141,000.91 [1].
Wall Street analysts have also been optimistic about Amgen's prospects. Several analysts have raised their ratings and target prices for the stock. For example, Piper Sandler raised their price target on shares of Amgen from $328.00 to $342.00 and gave the company an "overweight" rating [1]. Citigroup also upped their target price on shares of Amgen from $310.00 to $315.00 and gave the stock a "neutral" rating [1].
Amgen's financial performance has also been strong. The company reported $6.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.28 by $0.74 [1]. The company had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion [1]. Amgen had a net margin of 18.96% and a return on equity of 174.71% [1]. The firm's revenue was up 9.4% compared to the same quarter last year [1].
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were issued a dividend of $2.38 per share [1]. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2% [1].
In conclusion, Amgen Inc. (AMGN) has shown a significant shift in its stock price momentum, with bullish indicators such as the KDJ Golden Cross and Bullish Marubozu. Institutional investors and insiders have also shown increased confidence in the company, and Wall Street analysts have been optimistic about Amgen's prospects. The company's financial performance has also been strong, with a significant increase in earnings and revenue compared to the same quarter last year.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet